Tracking the litigation around Bayer’s Nexavar patent in India
For the last year or so, Bayer has been defending its Indian Patent No. 215758 for ‘sorafenib’, which is marketed under the brand name Nexavar and is targeted at patients suffering from liver and kidney cancers. (Image from here) As we had reported in April last year, Bayer had sued Cipla for patent infringement, while Cipla counter-sued for revocation of the patent on grounds of invalidity and suppression of vital Section 8 information. Earlier this year, Bayer sued NATCO before […]
Tracking the litigation around Bayer’s Nexavar patent in India Read More »